Biobetter Market
Biobetter Market Study by Erythropoietin Biobetters, G-CSF Biobetters, Interferon Biobetters, Insulin Biobetters, Monoclonal Antibodies Biobetters, and Antihemophilic Factors from 2024 to 2034
Analysis of Biobetter Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Biobetter Market Outlook (2024 to 2034)
The global biobetter market size is calculated at US$ 66.31 billion for 2024 and is forecast to reach US$ 150.75 billion by 2034, with a projected CAGR of 8.6% from 2024 to 2034.
Biobetter refers to an improved version of a biopharmaceutical product, typically a biological drug or therapeutic, that offers enhanced efficacy, safety, or other advantages compared to its predecessor. The term is often used in the context of biotechnology and the development of biologics, which are complex molecules derived from living cells.
Patients and healthcare providers are naturally drawn to treatments that provide better outcomes. Biobetter products often represent advancements in therapeutic options. They offer improved efficacy, safety profiles, or reduced side effects compared to existing biopharmaceuticals.
Ongoing developments in biotechnology, including protein engineering, cell line development, and improved manufacturing processes, are enabling the production of biobetter products with enhanced characteristics. With a growing focus on personalized medicine, there is an increasing demand for treatments that are more tailored to individual patient needs. Biobetter products are designed to address specific patient populations or provide personalized therapeutic benefits.
- Global demand for insulin biobetters is forecast to rise at a CAGR of 8.7% and reach a market value of US$ 69.38 billion by the end of 2034.
The rising prevalence of diabetes across the world is directly boosting demand for insulin products. Insulin biobetters, with potential improvements in efficacy, safety, and patient outcomes, are sought after to better address the needs of individuals with diabetes.
Insulin biobetters aim to optimize the therapeutic effects of insulin, such as improved glycemic control and a reduced risk of hypoglycemia. These advancements are particularly crucial for individuals with diabetes who require insulin to manage their blood sugar levels.
- North America is predicted to account for 52.4% of global biobetter market share by 2034.
- Sales of insulin biobetters in East Asia are forecasted to increase at a CAGR of 9.5% through 2034.
| Report Attributes | Details |
|---|---|
| Biobetter Market Size (2024E) | US$ 66.31 Billion |
| Forecasted Market Value (2034F) | US$ 150.75 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.6% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 7.7% CAGR |
| South Korea Market Value (2034F) | US$ 304.5 Million |
| Erythropoietin Biobetter Sales (2034F) | US$ 11.09 Billion |
| Antihemophilic Factor Demand Growth (2024 to 2034) | 8.1% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Market Dynamics are Generating Lucrative Opportunities for Biobetter Producers?
“Intense Competition in Biosimilar Manufacturing Leading to Shift toward Biobetter Production”
In response to the crowded biosimilar market, pharmaceutical companies are strategically shifting their focus toward the development of biobetters. Unlike biosimilars, which aim to replicate the structure and function of existing biologics, biobetters represent an innovative approach. Companies are investing heavily in research and development activities to create biobetters that go beyond mere replication, aiming to enhance therapeutic efficacy, safety, and overall patient outcomes.
Biobetters are designed to offer advancements in therapeutic effectiveness, providing a clear differentiator from biosimilars. This emphasis on improved efficacy positions biobetters as valuable alternatives for patients seeking enhanced treatment options. Safety considerations play a pivotal role in the development of biobetters. Companies aim to mitigate potential side effects, reduce immunogenicity, and enhance overall safety profiles, providing a critical advantage over biosimilar competitors.
“Biotechnology and Protein Engineering Advancements Enhancing Biobetter Effectiveness”
The biopharmaceutical landscape is undergoing a profound transformation, propelled by relentless advancements in biotechnology and protein engineering. This biobetter market trend is steering the development of next-generation biobetter products.
Breakthroughs in genetic engineering and molecular biology techniques are enabling precise manipulation of biological molecules. This precision allows scientists to engineer biobetters with targeted modifications, enhancing their therapeutic properties.
Innovations in protein folding studies and the enhancement of protein stability are contributing to the development of biobetters with improved shelf life and enhanced bioavailability. This ensures that the therapeutic agent retains its efficacy from production to administration.
What is Hampering Production of Biobetters?
“High Development Cost Exerting Financial Strain on Small Companies”
Early stages of biobetter development demand extensive research and development efforts. Small-scale companies, often lacking the financial resources of larger counterparts, struggle to allocate the necessary funds for robust preclinical research and optimization studies.
Adoption of cutting-edge biotechnological tools and state-of-the-art infrastructure is crucial for successful biobetter development. Small companies face challenges in making these essential investments, limiting their ability to compete with large, well-established counterparts. The substantial investment and high development costs associated with biobetter research and clinical trials represent a significant obstacle, acting as a formidable barrier to market entry for newcomers.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How are New Companies Strategizing in This Market?
“Increasing Partnerships with Established Players for Financial Support”
Successful entry into the biobetter industry requires a combination of strategic initiatives, collaboration, and a keen understanding of market dynamics. New entrants should strategically collaborate with established pharmaceutical companies, research institutions, or biotech firms. Partnerships offer shared resources, expertise, and potentially faster development timelines. Leveraging the strengths of established players can provide financial support and enhance the credibility of newcomers in the competitive market.
“Focus on Niche Therapeutic Areas to Gain High Profits”
New manufacturers can distinguish themselves by focusing on niche therapeutic areas where there may be unmet medical needs. Specialization allows for a targeted approach, potentially leading to faster development, regulatory approval, and market penetration. It also attracts attention from investors and stakeholders interested in specific therapeutic advancements.
Country-wise Analysis
Demand for biobetters in the United States, Germany, and Japan is driven by a combination of factors, including rising disease burden, biosimilar market competition, regulatory support, aging populations, and a commitment to biopharmaceutical innovation. Each country's unique healthcare landscape and priorities contribute to the specific drivers influencing the demand for biobetter products.
Why is the United States a Profitable Market for Biobetter Manufacturers?
“Increasing Incidence of Chronic Disorders Driving Use of Advanced Biobetters”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 32.44 Billion |
| Growth Rate (2024 to 2034) | 8.6% CAGR |
| Projected Value (2034F) | US$ 73.8 Billion |
The United States is experiencing a rising prevalence of chronic diseases, including cancer, autoimmune disorders, and diabetes. The biobetter market growth in the United States is driven by the need for more effective and advanced therapies to address the growing disease burden.
With patents expiring for several biologics, the United States market is witnessing intense competition, prompting companies to invest in the development of biobetters. The entry of biobetters is offering effective options for patients and healthcare providers, leading to high demand.
Why is Demand for Biobetters High in Germany?
“Presence of Advanced Healthcare Infrastructure and Favorable Reimbursement Policies”
Germany boasts a well-established and robust healthcare infrastructure. Demand for biobetters is driven by the country's commitment to providing cutting-edge medical treatments, which attracts investments in research and development efforts for innovative biopharmaceutical solutions.
Germany's efficient market access and reimbursement policies for pharmaceuticals are generating a conducive environment for biobetter development. Companies are incentivized to bring innovative therapies to market, fostering demand for biobetters.
Why Should Biobetter Manufacturers Invest in Japan?
“High Prevalence of Age-related Disorders and Growing Healthcare Needs”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 1.91 Billion |
| Growth Rate (2024 to 2034) | 8.5% CAGR |
| Projected Value (2034F) | US$ 4.34 Billion |
Due to its expanding aging population, Japan experiences a high incidence of diseases associated with old age. Demand for biobetters in the country is driven by the need for more effective and targeted therapies to address the unique healthcare challenges associated with an aging demographic.
Japanese pharmaceutical companies also often engage in global collaborations and technology transfer agreements, gaining access to advanced biotechnological tools. These collaborations are contributing to the development of biobetters with improved therapeutic profiles, meeting the demand for innovative treatments.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
According to Fact.MR, a market research and competitive intelligence provider, the accessibility, patient engagement, comprehensive services, and integration capabilities of retail pharmacies are making them major distribution channels for biobetters.
Why are Retail Pharmacies Key Distribution Channels for Biobetters?
“Easy Product Accessibility and Convenience of Retail Pharmacies”
| Attribute | Retail Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 40.18 Billion |
| Growth Rate (2024 to 2034) | 8.6% CAGR |
| Projected Value (2034F) | US$ 92.09 Billion |
Retail pharmacies are widely distributed and easily accessible to the general population. Patients can conveniently pick up their biobetter prescriptions at local pharmacies, enhancing overall accessibility and patient adherence to treatment plans. Retail pharmacies also offer comprehensive prescription filling services and medication management. Patients can easily drop off prescriptions from healthcare providers, and pharmacies ensure the timely availability of biobetter medications, supporting adherence and continuity of care.
Pharmacists at retail pharmacies often undergo continuous training and education on new medications, including biobetters. Their knowledge allows them to provide informed guidance to patients and address any concerns, contributing to the safe and effective use of biobetter therapies.
Competitive Landscape
Leading companies in the biobetter industry are focusing on allocating significant resources to research and development activities, aiming to create innovative biobetter products with improved therapeutic profiles. Investments in cutting-edge technologies and scientific advancements are positioning these companies at the forefront of the market. Key market players are also focusing on establishing a strong international presence to earn high profits.
Key Segments of Biobetter Market Research
-
By Drug Class :
- Erythropoietin Biobetters
- G-CSF Biobetters
- Interferon Biobetters
- Insulin Biobetters
- Monoclonal Antibodies Biobetters
- Antihemophilic Factors
- Others
-
By Disease Indication :
- Diabetes
- Cancer
- Renal Disease
- Neurodegenerative Diseases
- Genetic Disorder-Hemophilia
- Others
-
By Route of Administration :
- Subcutaneous
- Intravenous
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Key Findings 1.1.1. Overall Market 1.1.2. Segment Overview 1.1.3. Regional Overview 1.1.4. Competitor’s Focus 1.1.5. Consumer’s Perception 1.2. Summary of Statistics 1.3. Market Characteristics and Attributes 2. Market Overview 2.1. Introduction and Definition 2.2. Research Scope 3. COVID 19 Impact Assessment 3.1. Demand in Market 3.1.1. Global Market Quarterly Market Value Analysis (US$ Mn), 2023 3.1.2. Global Market Value Y-o-Y Growth Pre and Post Crisis Projection 3.1.3. Global Market Recalibrated Growth Projection (US$ Mn) 3.2. Market Shrink and Recovery Trend Assessment, by Region 3.3. Market Recalibrated Market and Growth Assessment, by Region 4. Market Background 4.1. Country-wise Market Attractiveness Index 4.2. Market Scenario-based Forecast 4.3. Value Chain Analysis 4.3.1. List of Manufacturers 4.3.2. List of Online Retailers 4.3.3. List of Distribution Channels 4.4. Investment Feasibility Assessment 4.4.1. Investment Feasibility for Market 4.5. Porter’s Five Forces Analysis 4.5.1. Bargaining Power of Buyers 4.5.2. Bargaining Power of Suppliers 4.5.3. Threat of Substitute Disease Indications 4.5.4. Threat of New Entrants 4.5.5. Intensity of Rivalry 4.5.6. 5 Forces Acting Upon Market 4.6. PESTEL Analysis 4.7. Forecast Factors 4.7.1. Increasing Government Regulations 4.7.2. Expansion of Industry 4.7.3. Compliance to Insurance Regulations 4.7.4. Advancements in Market 4.7.5. Increasing Global Temperature 4.7.6. Technological Advancements 4.8. Market Dynamics 4.8.1. Market Drivers 4.8.2. Market Restraints 4.8.3. Opportunity Windows 4.8.4. Key Trends 5. Global Market Pricing Analysis 5.1. Price Point Assessment 5.1.1. Weighted Average Pricing (2023), by Region 5.1.2. Key Factors Influencing Pricing 5.1.3. Price Benchmark by Region 5.1.4. Price Benchmark by Drug Class 6. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034) 6.1. Market Overview 6.2. Introduction to Market Statistics 6.2.1. Global Market Value (US$ Mn) 6.2.2. Global Cumulative Historical Market and Absolute $ Opportunity 6.3. Y-o-Y Growth and Incremental Opportunity 6.4. Absolute Dollar Historical Market and Absolute Dollar Opportunity 7. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Drug Class 7.1. Introduction 7.1.1. Drug Class Definition 7.1.1.1. Erythropoietin Biobetters 7.1.1.2. G-CSF Biobetters 7.1.1.3. Interferon Biobetters 7.1.1.4. Insulin Biobetters 7.1.1.5. Monoclonal Antibodies Biobetters 7.1.1.6. Antihemophilic Factors 7.1.1.7. Others 7.1.2. Market Key Findings, by Drug Class 7.1.2.1. Absolute $ Opportunity (2024 to 2034) 7.1.2.2. Market Share and BPS Analysis 7.1.2.3. Y-o-Y Growth Projections 7.1.2.4. Market Attractiveness Analysis 7.2. Global Market Regional Market Share Comparison, by Drug Class 8. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Disease Indication 8.1. Introduction 8.1.1. Disease Indication Definition 8.1.1.1. Diabetes 8.1.1.2. Cancer 8.1.1.3. Renal Disease 8.1.1.4. Neurodegenerative Diseases 8.1.1.5. Genetic Disorder-Hemophilia 8.1.1.6. Others 8.1.2. Market Key Findings, by Disease Indication 8.1.2.1. Absolute $ Opportunity (2024 to 2034) 8.1.2.2. Market Share and BPS Analysis 8.1.2.3. Y-o-Y Growth Projections 8.1.2.4. Market Attractiveness Analysis 8.2. Global Market Regional Market Share Comparison, by Disease Indication 9. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Route of Administration 9.1. Introduction 9.1.1. Route of Administration Definition 9.1.1.1. Subcutaneous 9.1.1.2. Intravenous 9.1.2. Market Key Findings, by Route of Administration 9.1.2.1. Absolute $ Opportunity (2024 to 2034) 9.1.2.2. Market Share and BPS Analysis 9.1.2.3. Y-o-Y Growth Projections 9.1.2.4. Market Attractiveness Analysis 9.2. Global Market Regional Market Share Comparison, by Route of Administration 10. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Distribution Channel 10.1. Introduction 10.1.1. Distribution Channel Definition 10.1.1.1. Hospital Pharmacies 10.1.1.2. Retail Pharmacies 10.1.1.3. Online Pharmacies 10.1.2. Market Key Findings, by Distribution Channel 10.1.2.1. Absolute $ Opportunity (2024 to 2034) 10.1.2.2. Share and BPS Analysis 10.1.2.3. Y-o-Y Growth Projections 10.1.2.4. Market Attractiveness Analysis 10.2. Global Market Regional Market Share Comparison, by Distribution Channel 11. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Region 11.1. Introduction 11.1.1. Regional Coverage 11.1.1.1. North America 11.1.1.2. Europe 11.1.1.3. East Asia 11.1.1.4. South Asia 11.1.1.5. Latin America 11.1.1.6. Middle East & Africa (MEA) 11.1.1.7. Oceania 11.1.2. Market Key Findings, by Region 11.1.2.1. Absolute $ Opportunity (2024 to 2034) 11.1.2.2. Market Share and BPS Analysis 11.1.2.3. Y-o-Y Growth Projections 11.1.2.4. Market Attractiveness Analysis 11.2. Global Market Regional Market Share Comparison, by Region 12. North America Market Analysis and Forecast 12.1. Overview 12.1.1. North America Share in Global Market 12.2. Market Value & Volume Forecast and Analysis 12.2.1. By Country 12.2.1.1. United States 12.2.1.2. Canada 12.2.2. By Drug Class 12.2.3. By Disease Indication 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.1.1. United States 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Disease Indication 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Y-o-Y Growth Comparison 13. Europe Market Analysis and Forecast 13.1. Overview 13.1.1. Europe Share in Global Market 13.2. Market Value & Volume Forecast and Analysis 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Russia 13.2.1.5. Spain 13.2.1.6. Italy 13.2.1.7. Rest of Europe 13.2.2. By Drug Class 13.2.3. By Disease Indication 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. United Kingdom 13.3.1.3. France 13.3.1.4. Russia 13.3.1.5. Spain 13.3.1.6. Italy 13.3.1.7. Rest of Europe 13.3.2. By Drug Class 13.3.3. By Disease Indication 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Y-o-Y Growth Comparison 14. East Asia Market Analysis and Forecast 14.1. Overview 14.1.1. East Asia Share in Global Market 14.2. Market Value & Volume Forecast and Analysis 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Disease Indication 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Drug Class 14.3.3. By Disease Indication 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Y-o-Y Growth Comparison 15. South Asia Market Analysis and Forecast 15.1. Overview 15.1.1. South Asia Share in Global Market 15.2. Market Value & Volume Forecast and Analysis 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Singapore 15.2.1.3. Indonesia 15.2.1.4. Thailand 15.2.1.5. Rest of South Asia 15.2.2. By Drug Class 15.2.3. By Disease Indication 15.2.4. By Route of Administration 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Singapore 15.3.1.3. Indonesia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Drug Class 15.3.3. By Disease Indication 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Y-o-Y Growth Comparison 16. Latin America Market Analysis and Forecast 16.1. Overview 16.1.1. Latin America Share in Global Market 16.2. Market Value & Volume Forecast and Analysis 16.2.1. By Country 16.2.1.1. Brazil 16.2.1.2. Mexico 16.2.1.3. Rest of LATAM 16.2.2. By Drug Class 16.2.3. By Disease Indication 16.2.4. By Route of Administration 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Rest of LATAM 16.3.2. By Drug Class 16.3.3. By Disease Indication 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Y-o-Y Growth Comparison 17. Middle East & Africa Market Analysis and Forecast 17.1. Overview 17.1.1. Middle East & Africa Share in Global Market 17.2. Market Value & Volume Forecast and Analysis 17.2.1. By Country 17.2.1.1. Turkey 17.2.1.2. GCC Countries 17.2.1.3. Rest of MEA 17.2.2. By Drug Class 17.2.3. By Disease Indication 17.2.4. By Route of Administration 17.2.5. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.1.1. Turkey 17.3.1.2. GCC Countries 17.3.1.3. Rest of MEA 17.3.2. By Drug Class 17.3.3. By Disease Indication 17.3.4. By Route of Administration 17.3.5. By Distribution Channel 17.4. Y-o-Y Growth Comparison 18. Oceania Market Analysis and Forecast 18.1. Overview 18.1.1. Oceania Share in Global Market 18.2. Market Value & Volume Forecast and Analysis 18.2.1. By Country 18.2.1.1. Australia 18.2.1.2. New Zealand 18.2.2. By Drug Class 18.2.3. By Disease Indication 18.2.4. By Route of Administration 18.2.5. By Distribution Channel 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Class 18.3.3. By Disease Indication 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 18.4. Y-o-Y Growth Comparison 19. Global Market Analysis Key Countries 19.1. United States 19.1.1. Share of North American Market 19.1.2. Market Share, by Drug Class, 2023 19.1.3. Market Share, by Disease Indication, 2023 19.1.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.1.5. Market Share, by Distribution Channel, 2023 19.2. Canada 19.2.1. Share of North American Market 19.2.2. Market Share, by Drug Class, 2023 19.2.3. Market Share, by Disease Indication, 2023 19.2.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.2.5. Market Share, by Distribution Channel, 2023 19.3. Germany 19.3.1. Share of European Market 19.3.2. Market Share, by Drug Class, 2023 19.3.3. Market Share, by Disease Indication, 2023 19.3.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.3.5. Market Share, by Distribution Channel, 2023 19.4. United Kingdom 19.4.1. Share of European Market 19.4.2. Market Share, by Drug Class, 2023 19.4.3. Market Share, by Disease Indication, 2023 19.4.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.4.5. Market Share, by Distribution Channel, 2023 19.5. France 19.5.1. Share of European Market 19.5.2. Market Share, by Drug Class, 2023 19.5.3. Market Share, by Disease Indication, 2023 19.5.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.5.5. Market Share, by Distribution Channel, 2023 19.6. Russia 19.6.1. Share of European Market 19.6.2. Market Share, by Drug Class, 2023 19.6.3. Market Share, by Disease Indication, 2023 19.6.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.6.5. Market Share, by Distribution Channel, 2023 19.7. Spain 19.7.1. Share of European Market 19.7.2. Market Share, by Drug Class, 2023 19.7.3. Market Share, by Disease Indication, 2023 19.7.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.7.5. Market Share, by Distribution Channel, 2023 19.8. Italy 19.8.1. Share of European Market 19.8.2. Market Share, by Drug Class, 2023 19.8.3. Market Share, by Disease Indication, 2023 19.8.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.8.5. Market Share, by Distribution Channel, 2023 19.9. China 19.9.1. Share of East Asian Market 19.9.2. Market Share, by Drug Class, 2023 19.9.3. Market Share, by Disease Indication, 2023 19.9.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.9.5. Market Share, by Distribution Channel, 2023 19.10. Japan 19.10.1. Share of East Asian Market 19.10.2. Market Share, by Drug Class, 2023 19.10.3. Market Share, by Disease Indication, 2023 19.10.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.10.5. Market Share, by Distribution Channel, 2023 19.11. South Korea 19.11.1. Share of East Asian Market 19.11.2. Market Share, by Drug Class, 2023 19.11.3. Market Share, by Disease Indication, 2023 19.11.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.11.5. Market Share, by Distribution Channel, 2023 19.12. India 19.12.1. Share of South Asian Market 19.12.2. Market Share, by Drug Class, 2023 19.12.3. Market Share, by Disease Indication, 2023 19.12.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.12.5. Market Share, by Distribution Channel, 2023 19.13. Singapore 19.13.1. Share of South Asian Market 19.13.2. Market Share, by Drug Class, 2023 19.13.3. Market Share, by Disease Indication, 2023 19.13.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.13.5. Market Share, by Distribution Channel, 2023 19.14. Indonesia 19.14.1. Share of South Asian Market 19.14.2. Market Share, by Drug Class, 2023 19.14.3. Market Share, by Disease Indication, 2023 19.14.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.14.5. Market Share, by Distribution Channel, 2023 19.15. Thailand 19.15.1. Share of South Asian Market 19.15.2. Market Share, by Drug Class, 2023 19.15.3. Market Share, by Disease Indication, 2023 19.15.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.15.5. Market Share, by Distribution Channel, 2023 19.16. Brazil 19.16.1. Share of Latin American Market 19.16.2. Market Share, by Drug Class, 2023 19.16.3. Market Share, by Disease Indication, 2023 19.16.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.16.5. Market Share, by Distribution Channel, 2023 19.17. Mexico 19.17.1. Share of Latin American Market 19.17.2. Market Share, by Drug Class, 2023 19.17.3. Market Share, by Disease Indication, 2023 19.17.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.17.5. Market Share, by Distribution Channel, 2023 19.18. Turkey 19.18.1. Share of MEA Market 19.18.2. Market Share, by Drug Class, 2023 19.18.3. Market Share, by Disease Indication, 2023 19.18.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.18.5. Market Share, by Distribution Channel, 2023 19.19. GCC Countries 19.19.1. Share of MEA Market 19.19.2. Market Share, by Drug Class, 2023 19.19.3. Market Share, by Disease Indication, 2023 19.19.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.19.5. Market Share, by Distribution Channel, 2023 19.20. South Africa 19.20.1. Share of MEA Market 19.20.2. Market Share, by Drug Class, 2023 19.20.3. Market Share, by Disease Indication, 2023 19.20.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.20.5. Market Share, by Distribution Channel, 2023 19.21. Australia 19.21.1. Share of Oceania Market 19.21.2. Market Share, by Drug Class, 2023 19.21.3. Market Share, by Disease Indication, 2023 19.21.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.21.5. Market Share, by Distribution Channel, 2023 19.22. New Zealand 19.22.1. Share of Oceania Market 19.22.2. Market Share, by Drug Class, 2023 19.22.3. Market Share, by Disease Indication, 2023 19.22.4. Market Value (US$ Mn) and Forecast 2024 to 2034 19.22.5. Market Share, by Distribution Channel, 2023 20. Competition Landscape 20.1. Global Market Competition Dashboard 20.2. Global Market Tier Structure 20.2.1. Market Structure in 2023 20.2.2. Anticipated Market Structure in 2034 20.3. Global Market Share Analysis 21. Competition Analysis 21.1. CSL Behring GmbH 21.1.1. Company Overview 21.1.2. Disease Indication Portfolio 21.1.3. Key Strategies 21.1.4. Regional Presence 21.1.5. Key Developments 21.1.6. SWOT Analysis 21.2. Teva Pharmaceutical Industries Ltd. 21.2.1. Company Overview 21.2.2. Disease Indication Portfolio 21.2.3. Key Strategies 21.2.4. Regional Presence 21.2.5. Key Developments 21.2.6. SWOT Analysis 21.3. F.Hoffmann-La Roche AG 21.3.1. Company Overview 21.3.2. Disease Indication Portfolio 21.3.3. Key Strategies 21.3.4. Regional Presence 21.3.5. Key Developments 21.3.6. SWOT Analysis 21.4. Merck & Co. Inc. 21.4.1. Company Overview 21.4.2. Disease Indication Portfolio 21.4.3. Key Strategies 21.4.4. Regional Presence 21.4.5. Key Developments 21.4.6. SWOT Analysis 21.5. Sanofi SA 21.5.1. Company Overview 21.5.2. Disease Indication Portfolio 21.5.3. Key Strategies 21.5.4. Regional Presence 21.5.5. Key Developments 21.5.6. SWOT Analysis 21.6. Eli Lily and Company 21.6.1. Company Overview 21.6.2. Disease Indication Portfolio 21.6.3. Key Strategies 21.6.4. Regional Presence 21.6.5. Key Developments 21.6.6. SWOT Analysis 21.7. Novo Nordisk A/S 21.7.1. Company Overview 21.7.2. Disease Indication Portfolio 21.7.3. Key Strategies 21.7.4. Regional Presence 21.7.5. Key Developments 21.7.6. SWOT Analysis 21.8. Biogen Inc. 21.8.1. Company Overview 21.8.2. Disease Indication Portfolio 21.8.3. Key Strategies 21.8.4. Regional Presence 21.8.5. Key Developments 21.8.6. SWOT Analysis 21.9. SERVIER 21.9.1. Company Overview 21.9.2. Disease Indication Portfolio 21.9.3. Key Strategies 21.9.4. Regional Presence 21.9.5. Key Developments 21.9.6. SWOT Analysis 21.10. Porton Biopharma Limited 21.10.1. Company Overview 21.10.2. Disease Indication Portfolio 21.10.3. Key Strategies 21.10.4. Regional Presence 21.10.5. Key Developments 21.10.6. SWOT Analysis 22. Appendix 23. Definitions of Analytical Frameworks 24. Sources and References
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market by Drug Class, 2018 to 2034
Table 02: Global Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 03: Global Market by Disease Indication, 2018 to 2034
Table 04: Global Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 05: Global Market by Route of Administration, 2018 to 2034
Table 06: Global Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 07: Global Market by Distribution Channel, 2018 to 2034
Table 08: Global Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 09: Global Market by Region, 2018 to 2034
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2034
Table 11: North America Market by Drug Class, 2018 to 2034
Table 12: North America Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 13: North America Market by Disease Indication, 2018 to 2034
Table 14: North America Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 15: North America Market by Route of Administration, 2018 to 2034
Table 16: North America Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 17: North America Market by Distribution Channel, 2018 to 2034
Table 18: North America Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 19: North America Market by Country, 2018 to 2034
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2034
Table 21: Europe Market by Drug Class, 2018 to 2034
Table 22: Europe Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 23: Europe Market by Disease Indication, 2018 to 2034
Table 24: Europe Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 25: Europe Market by Route of Administration, 2018 to 2034
Table 26: Europe Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 27: Europe Market by Distribution Channel, 2018 to 2034
Table 28: Europe Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 29: Europe Market by Country, 2018 to 2034
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2034
Table 31: East Asia Market by Drug Class, 2018 to 2034
Table 32: East Asia Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 33: East Asia Market by Disease Indication, 2018 to 2034
Table 34: East Asia Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 35: East Asia Market by Route of Administration, 2018 to 2034
Table 36: East Asia Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 37: East Asia Market by Distribution Channel, 2018 to 2034
Table 38: East Asia Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 39: East Asia Market by Country, 2018 to 2034
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 41: South Asia Market by Drug Class, 2018 to 2034
Table 42: South Asia Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 43: South Asia Market by Disease Indication, 2018 to 2034
Table 44: South Asia Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 45: South Asia Market by Route of Administration, 2018 to 2034
Table 46: South Asia Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 47: South Asia Market by Distribution Channel, 2018 to 2034
Table 48: South Asia Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 49: South Asia Market by Country, 2018 to 2034
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 51: Latin America Market by Drug Class, 2018 to 2034
Table 52: Latin America Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 53: Latin America Market by Disease Indication, 2018 to 2034
Table 54: Latin America Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 55: Latin America Market by Route of Administration, 2018 to 2034
Table 56: Latin America Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 57: Latin America Market by Distribution Channel, 2018 to 2034
Table 58: Latin America Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 59: Latin America Market by Country, 2018 to 2034
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2034
Table 61: Middle East and Africa Market by Drug Class, 2018 to 2034
Table 62: Middle East and Africa Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 63: Middle East and Africa Market by Disease Indication, 2018 to 2034
Table 64: Middle East and Africa Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 65: Middle East and Africa Market by Route of Administration, 2018 to 2034
Table 66: Middle East and Africa Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 67: Middle East and Africa Market by Distribution Channel, 2018 to 2034
Table 68: Middle East and Africa Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 69: Middle East and Africa Market by Country, 2018 to 2034
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2034
Table 71: Oceania Market by Drug Class, 2018 to 2034
Table 72: Oceania Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 73: Oceania Market by Disease Indication, 2018 to 2034
Table 74: Oceania Market Value (US$ Mn), by Disease Indication, 2018 to 2034
Table 75: Oceania Market by Route of Administration, 2018 to 2034
Table 76: Oceania Market Value (US$ Mn), by Route of Administration, 2018 to 2034
Table 77: Oceania Market by Distribution Channel, 2018 to 2034
Table 78: Oceania Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 79: Oceania Market by Country, 2018 to 2034
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig 01: Global Market Value (US$) and Y-o-Y Growth, 2018 to 2034
Fig 02: Global Absolute $ Historical Market (2018 to 2023) and Absolute $ Opportunity (2024 to 2034), US$ Mn
Fig 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2034
Fig 04: Global Market Incremental $ Opportunity (US$ Thousand), 2024 to 2034
Fig 05: Global Market Share, By Drug Class – 2024 to 2034
Fig 06: Global Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 07: Global Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 08: Global Market Share, By Disease Indication – 2024 to 2034
Fig 09: Global Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 10: Global Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 11: Global Market Share, By Route of Administration – 2024 to 2034
Fig 12: Global Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 13: Global Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 14: Global Market Share, By Distribution Channel – 2024 to 2034
Fig 15: Global Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 16: Global Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 17: Global Market Share, by Region – 2024 to 2034
Fig 18: Global Market Y-o-Y Growth Projections, by Region – 2024 to 2034
Fig 19: Global Market Attractiveness Index, by Region – 2024 to 2034
Fig 20: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Fig 21: North America Market Share, By Drug Class – 2024 to 2034
Fig 22: North America Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 23: North America Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 24: North America Market Share, By Disease Indication – 2024 to 2034
Fig 25: North America Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 26: North America Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 27: North America Market Share, By Route of Administration – 2024 to 2034
Fig 28: North America Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 29: North America Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 30: North America Market Share, By Distribution Channel – 2024 to 2034
Fig 31: North America Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 32: North America Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 33: North America Market Share, By Country – 2024 to 2034
Fig 34: North America Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 35: North America Market Attractiveness Index, By Country – 2024 to 2034
Fig 36: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Fig 37: Europe Market Share, By Drug Class – 2024 to 2034
Fig 38: Europe Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 39: Europe Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 40: Europe Market Share, By Disease Indication – 2024 to 2034
Fig 41: Europe Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 42: Europe Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 43: Europe Market Share, By Route of Administration – 2024 to 2034
Fig 44: Europe Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 45: Europe Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 46: Europe Market Share, By Distribution Channel – 2024 to 2034
Fig 47: Europe Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 48: Europe Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 49: Europe Market Share, By Country – 2024 to 2034
Fig 50: Europe Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 51: Europe Market Attractiveness Index, By Country – 2024 to 2034
Fig 52: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 53: East Asia Market Share, By Drug Class – 2024 to 2034
Fig 54: East Asia Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 55: East Asia Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 56: East Asia Market Share, By Disease Indication – 2024 to 2034
Fig 57: East Asia Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 58: East Asia Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 59: East Asia Market Share, By Route of Administration – 2024 to 2034
Fig 60: East Asia Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 61: East Asia Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 62: East Asia Market Share, By Distribution Channel – 2024 to 2034
Fig 63: East Asia Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 64: East Asia Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 65: East Asia Market Share, By Country – 2024 to 2034
Fig 66: East Asia Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 67: East Asia Market Attractiveness Index, By Country – 2024 to 2034
Fig 68: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 69: South Asia Market Share, By Drug Class – 2024 to 2034
Fig 70: South Asia Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 71: South Asia Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 72: South Asia Market Share, By Disease Indication – 2024 to 2034
Fig 73: South Asia Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 74: South Asia Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 75: South Asia Market Share, By Route of Administration – 2024 to 2034
Fig 76: South Asia Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 77: South Asia Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 78: South Asia Market Share, By Distribution Channel – 2024 to 2034
Fig 78: South Asia Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 80: South Asia Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 81: South Asia Market Share, By Country – 2024 to 2034
Fig 82: South Asia Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 83: South Asia Market Attractiveness Index, By Country – 2024 to 2034
Fig 84: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 85: Latin America Market Share, By Drug Class – 2024 to 2034
Fig 86: Latin America Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 87: Latin America Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 88: Latin America Market Share, By Disease Indication – 2024 to 2034
Fig 89: Latin America Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 90: Latin America Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 91: Latin America Market Share, By Route of Administration – 2024 to 2034
Fig 92: Latin America Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 93: Latin America Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 94: Latin America Market Share, By Distribution Channel – 2024 to 2034
Fig 95: Latin America Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 96: Latin America Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 97: Latin America Market Share, By Country – 2024 to 2034
Fig 98: Latin America Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 99: Latin America Market Attractiveness Index, By Country – 2024 to 2034
Fig 100: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Fig 101: MEA Market Share, By Drug Class – 2024 to 2034
Fig 102: MEA Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 103: MEA Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 104: MEA Market Share, By Disease Indication – 2024 to 2034
Fig 105: MEA Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 106: MEA Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 107: MEA Market Share, By Route of Administration – 2024 to 2034
Fig 108: MEA Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 109: MEA Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 110: MEA Market Share, By Distribution Channel – 2024 to 2034
Fig 111: MEA Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 112: MEA Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 113: MEA Market Share, By Country – 2024 to 2034
Fig 114: MEA Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 115: MEA Market Attractiveness Index, By Country – 2024 to 2034
Fig 116: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 117: Oceania Market Share, By Drug Class – 2024 to 2034
Fig 118: Oceania Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 119: Oceania Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 120: Oceania Market Share, By Disease Indication – 2024 to 2034
Fig 121: Oceania Market Y-o-Y Growth Projections, By Disease Indication – 2024 to 2034
Fig 122: Oceania Market Attractiveness Index, By Disease Indication – 2024 to 2034
Fig 123: Oceania Market Share, By Route of Administration – 2024 to 2034
Fig 124: Oceania Market Y-o-Y Growth Projections, By Route of Administration – 2024 to 2034
Fig 125: Oceania Market Attractiveness Index, By Route of Administration – 2024 to 2034
Fig 126: Oceania Market Share, By Distribution Channel – 2024 to 2034
Fig 127: Oceania Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 128: Oceania Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 129: Oceania Market Share, By Country – 2024 to 2034
Fig 130: Oceania Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 131: Oceania Market Attractiveness Index, By Country – 2024 to 2034
Fig 132: United States Market share by Drug Class, 2023
Fig 133: United States Market share by Disease Indication, 2023
Fig 134: United States Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 135: United States Market Share by Distribution Channel, 2023
Fig 136: Canada Market share by Drug Class, 2023
Fig 137: Canada Market share by Disease Indication, 2023
Fig 138: Canada Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 139: Canada Market Share by Distribution Channel, 2023
Fig 140: Germany Market share by Drug Class, 2023
Fig 141: Germany Market share by Disease Indication, 2023
Fig 142: Germany Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 143: Germany Market Share by Distribution Channel, 2023
Fig 144: United Kingdom Market share by Drug Class, 2023
Fig 145: United Kingdom Market share by Disease Indication, 2023
Fig 146: United Kingdom Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 147: United Kingdom Market Share by Distribution Channel, 2023
Fig 148: France Market share by Drug Class, 2023
Fig 149: France Market share by Disease Indication, 2023
Fig 150: France Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 151: France Market Share by Distribution Channel, 2023
Fig 152: Russia Market share by Drug Class, 2023
Fig 153: Russia Market share by Disease Indication, 2023
Fig 154: Russia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 155: Russia Market Share by Distribution Channel, 2023
Fig 156: Spain Market share by Drug Class, 2023
Fig 157: Spain Market share by Disease Indication, 2023
Fig 158: Spain Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 159: Spain Market Share by Distribution Channel, 2023
Fig 160: Italy Market share by Drug Class, 2023
Fig 161: Italy Market share by Disease Indication, 2023
Fig 162: Italy Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 163: Italy Market Share by Distribution Channel, 2023
Fig 164: China Market share by Drug Class, 2023
Fig 165: China Market share by Disease Indication, 2023
Fig 166: China Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 167: China Market Share by Distribution Channel, 2023
Fig 168: Japan Market share by Drug Class, 2023
Fig 169: Japan Market share by Disease Indication, 2023
Fig 170: Japan Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 171: Japan Market Share by Distribution Channel, 2023
Fig 172: South Korea Market share by Drug Class, 2023
Fig 173: South Korea Market share by Disease Indication, 2023
Fig 174: South Korea Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 175: South Korea Market Share by Distribution Channel, 2023
Fig 176: India Market share by Drug Class, 2023
Fig 177: India Market share by Disease Indication, 2023
Fig 178: India Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 179: India Market Share by Distribution Channel, 2023
Fig 180: Singapore Market share by Drug Class, 2023
Fig 181: Singapore Market share by Disease Indication, 2023
Fig 182: Singapore Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 183: Singapore Market Share by Distribution Channel, 2023
Fig 184: Indonesia Market share by Drug Class, 2023
Fig 185: Indonesia Market share by Disease Indication, 2023
Fig 186: Indonesia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 187: Indonesia Market Share by Distribution Channel, 2023
Fig 188: Thailand Market share by Drug Class, 2023
Fig 189: Thailand Market share by Disease Indication, 2023
Fig 190: Thailand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 191: Thailand Market Share by Distribution Channel, 2023
Fig 192: Brazil Market share by Drug Class, 2023
Fig 193: Brazil Market share by Disease Indication, 2023
Fig 194: Brazil Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 195: Brazil Market Share by Distribution Channel, 2023
Fig 196: Mexico Market share by Drug Class, 2023
Fig 197: Mexico Market share by Disease Indication, 2023
Fig 198: Mexico Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 199: Mexico Market Share by Distribution Channel, 2023
Fig 200: Turkey Market share by Drug Class, 2023
Fig 201: Turkey Market share by Disease Indication, 2023
Fig 202: Turkey Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 203: Turkey Market Share by Distribution Channel, 2023
Fig 204: GCC Countries Market share by Drug Class, 2023
Fig 205: GCC Countries Market share by Disease Indication, 2023
Fig 206: GCC Countries Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 207: GCC Countries Market Share by Distribution Channel, 2023
Fig 208: South Africa Market share by Drug Class, 2023
Fig 209: South Africa Market share by Disease Indication, 2023
Fig 210: South Africa Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 211: South Africa Market Share by Distribution Channel, 2023
Fig 212: Australia Market share by Drug Class, 2023
Fig 213: Australia Market share by Disease Indication, 2023
Fig 214: Australia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 215: Australia Market Share by Distribution Channel, 2023
Fig 216: New Zealand Market share by Drug Class, 2023
Fig 217: New Zealand Market share by Disease Indication, 2023
Fig 218: New Zealand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 219: New Zealand Market Share by Distribution Channel, 2023
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the biobetter market in 2024?
The global biobetter market is estimated at US$ 66.31 billion in 2024.
What is the sales value of biobetters in the United States?
Sales of biobetters in the United States are pegged at US$ 32.44 billion for 2024.
What share of the market do insulin biobetters occupy?
Insulin biobetters are estimated to hold a market share of 45.6% in 2024.
What is the sales forecast for biobetters by the end of 2034?
By 2034-end, worldwide sales of biobetters are projected to reach US$ 150.75 billion.
What is the demand growth projection for biobetters through 2034?
Global demand for biobetters is forecasted to rise at a CAGR of 8.6% from 2024 to 2034.
Who are the top producers of biobetters?
Some of the leading biobetter manufacturers are F. Hoffman-La Roche AG, Merck & Co. Inc., and Sanofi SA.
Biobetter Market